The degree of mucosal atrophy is associated with post-endoscopic submucosal dissection bleeding in early gastric cancer.


Journal

Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909

Informations de publication

Date de publication:
May 2022
Historique:
revised: 11 11 2021
received: 23 07 2021
accepted: 12 01 2022
pubmed: 9 2 2022
medline: 12 5 2022
entrez: 8 2 2022
Statut: ppublish

Résumé

Despite the widespread use of endoscopic submucosal dissection (ESD) for early gastric cancer, post-ESD bleeding remains a significant problem. Intragastric pH plays an important role in intragastric bleeding. Because gastric acid secretion contributes to intragastric pH, both the presence or absence of Helicobacter pylori infection and the degree of gastric mucosal atrophy may affect bleeding. The present study aimed to clarify the relationship between post-ESD bleeding and the degree of gastric mucosal atrophy based on H. pylori infection status. We included 8170 patients who underwent ESD for early gastric cancer at 33 hospitals in Japan from November 2013 to October 2016. We analyzed the risk factors contributing to post-ESD bleeding. There were 3935 H. pylori-positive patients and 4235 H. pylori-negative patients. A nonsevere degree of gastric mucosal atrophy was an independent risk factor for post-ESD bleeding in H. pylori-negative patients (odds ratio: 1.51, P = 0.007), but not in H. pylori-positive patients (odds ratio: 0.91, P = 0.600). Further, in H. pylori-negative, but not H. pylori-positive, patients, the rate of post-ESD bleeding increased in a stepwise manner for patients continuing antithrombotic drug use, patients who withdrew antithrombotic drug use, and antithrombotic drug nonusers. Nonsevere gastric mucosal atrophy was a risk factor for post-ESD bleeding in early gastric cancer in H. pylori-negative patients but not in H. pylori-positive patients.

Sections du résumé

BACKGROUND AND AIM OBJECTIVE
Despite the widespread use of endoscopic submucosal dissection (ESD) for early gastric cancer, post-ESD bleeding remains a significant problem. Intragastric pH plays an important role in intragastric bleeding. Because gastric acid secretion contributes to intragastric pH, both the presence or absence of Helicobacter pylori infection and the degree of gastric mucosal atrophy may affect bleeding. The present study aimed to clarify the relationship between post-ESD bleeding and the degree of gastric mucosal atrophy based on H. pylori infection status.
METHODS METHODS
We included 8170 patients who underwent ESD for early gastric cancer at 33 hospitals in Japan from November 2013 to October 2016. We analyzed the risk factors contributing to post-ESD bleeding.
RESULTS RESULTS
There were 3935 H. pylori-positive patients and 4235 H. pylori-negative patients. A nonsevere degree of gastric mucosal atrophy was an independent risk factor for post-ESD bleeding in H. pylori-negative patients (odds ratio: 1.51, P = 0.007), but not in H. pylori-positive patients (odds ratio: 0.91, P = 0.600). Further, in H. pylori-negative, but not H. pylori-positive, patients, the rate of post-ESD bleeding increased in a stepwise manner for patients continuing antithrombotic drug use, patients who withdrew antithrombotic drug use, and antithrombotic drug nonusers.
CONCLUSIONS CONCLUSIONS
Nonsevere gastric mucosal atrophy was a risk factor for post-ESD bleeding in early gastric cancer in H. pylori-negative patients but not in H. pylori-positive patients.

Identifiants

pubmed: 35132695
doi: 10.1111/jgh.15793
doi:

Substances chimiques

Fibrinolytic Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

870-877

Subventions

Organisme : Japanese Foundation for Research and Promotion of Endoscopy

Informations de copyright

© 2022 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Références

Ono H, Kondo H, Gotoda T et al. Endoscopic mucosal resection for treatment of early gastric cancer. Gut 2001; 48: 225-229.
Oda I, Suzuki H, Nonaka S, Yoshinaga S. Complications of gastric endoscopic submucosal dissection. Dig. Endosc. 2013; 25: 71-78.
Fujimoto K, Fujishiro M, Kato M et al. Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment. Dig. Endosc. 2014; 26: 1-14.
Hatta W, Tsuji Y, Yoshio T et al. Prediction model of bleeding after endoscopic submucosal dissection for early gastric cancer: BEST-J score. Gut 2021; 70: 476-484.
Green FW, Kaplan MM, Curtis LE, Levine PH. Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage. Gastroenterology 1978; 74: 38-43.
Uedo N, Takeuchi Y, Yamada T et al. Effect of a proton pump inhibitor or an H2-receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal dissection of early gastric cancer: a prospective randomized controlled trial. Am. J. Gastroenterol. 2007; 102: 1610-1616.
Yang Z, Wu Q, Liu Z, Wu K, Fan D. Proton pump inhibitors versus histamine-2-receptor antagonists for the management of iatrogenic gastric ulcer after endoscopic mucosal resection or endoscopic submucosal dissection: a meta-analysis of randomized trials. Digestion 2011; 84: 315-320.
Ono S, Kato M, Suzuki M et al. Frequency of Helicobacter pylori-negative gastric cancer and gastric mucosal atrophy in a Japanese endoscopic submucosal dissection series including histological, endoscopic and serological atrophy. Digestion 2012; 86: 59-65.
Matsuo T, Ito M, Takata S, Tanaka S, Yoshihara M, Chayama K. Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese. Helicobacter 2011; 16: 415-419.
Iijima K, Koike T, Sekine H et al. Sustained epithelial proliferation in a functionally irreversible fundic mucosa after Helicobacter pylori eradication. J. Gastroenterol. 2009; 44: 47-55.
Kakushima N, Fujishiro M, Yahagi N et al. Helicobactor pylori status and the extent of gastric atrophy do not affect ulcer healing after endoscopic submucosal dissection. J. Gastroenterol. Hepatol. 2006; 21: 1586-1589.
Mochizuki S, Uedo N, Oda I et al. Scheduled second-look endoscopy is not recommended after endoscopic submucosal dissection for gastric neoplasms (the SAFE trial): a multicentre prospective randomised controlled non-inferiority trial. Gut 2015; 64: 397-405.
Satoh K, Kimura K, Taniguchi Y et al. Distribution of inflammation and atrophy in the stomach of Helicobacter pylori-positive and -negative patients with chronic gastritis. Am. J. Gastroenterol. 1996; 91: 963-969.
Marcus EA, Inatomi N, Nagami GT, Sachs G, Scott DR. The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin. Aliment. Pharmacol. Ther. 2012; 36: 972-979.
Li Y, Sha W, Nie Y et al. Effect of intragastric pH on control of peptic ulcer bleeding. J. Gastroenterol. Hepatol. 2000; 15: 148-154.
Smolka AJ, Backert S. How Helicobacter pylori infection controls gastric acid secretion. J. Gastroenterol. 2012; 47: 609-618.
Tucci A, Poli L, Biasco G et al. Helicobacter pylori infection and gastric function in patients with fundic atrophic gastritis. Dig. Dis. Sci. 2001; 46: 1573-1583.
Haruma K, Mihara M, Okamoto E et al. Eradication of Helicobacter pylori increases gastric acidity in patients with atrophic gastritis of the corpus-evaluation of 24-h pH monitoring. Aliment. Pharmacol. Ther. 1999; 13: 155-162.
Sekine H, Iijima K, Koike T et al. Regional differences in the recovery of gastric acid secretion after Helicobacter pylori eradication: evaluations with Congo red chromoendoscopy. Gastrointest. Endosc. 2006; 64: 678-685.
El-Omar EM. Mechanisms of increased acid secretion after eradication of Helicobacter pylori infection. Gut 2006; 55: 144-146.
Kodama M, Murakami K, Okimoto T et al. Helicobacter pylori eradication improves gastric atrophy and intestinal metaplasia in long-term observation. Digestion 2012; 85: 126-130.
Iijima K, Koike T, Shimosegawa T. Reflux esophagitis triggered after Helicobacter pylori eradication: a noteworthy demerit of eradication therapy among the Japanese? Front. Microbiol. 2015; 6: 566.
Katelaris PH, Seow F, Lin BP, Napoli J, Ngu MC, Jones DB. Effect of age, Helicobacter pylori infection, and gastritis with atrophy on serum gastrin and gastric acid secretion in healthy men. Gut 1993; 34: 1032-1037.
Kishikawa H, Nishida J, Ichikawa H et al. Fasting gastric pH of Japanese subjects stratified by IgG concentration against Helicobacter pylori and pepsinogen status. Helicobacter 2011; 16: 427-433.
Iijima K, Sekine H, Koike T, Imatani A, Ohara S, Shimosegawa T. Long-term effect of Helicobacter pylori eradication on the reversibility of acid secretion in profound hypochlorhydria. Aliment. Pharmacol. Ther. 2004; 19: 1181-1188.
Patchett SE, O'Donoghue DP. Pharmacological manipulation of gastric juice: thrombelastographic assessment and implications for treatment of gastrointestinal haemorrhage. Gut 1995; 36: 358-362.
Waldum HL, Kleveland PM, Sørdal ØF. H. pylori and gastric acid: an intimate and reciprocal relationship. Therap. Adv. Gastroenterol. 2016; 9: 836-844.
Kaneko H, Konagaya T, Kusugami K. Helicobacter pylori and gut hormones. J. Gastroenterol. 2002; 37: 77-86.
Yoshii S, Yamada T, Yamaguchi S et al. Efficacy of vonoprazan for the prevention of bleeding after gastric endoscopic submucosal dissection with continuous use of antiplatelet agents. Endosc Int Open 2020; 8: E481-E487.
Abe H, Hatta W, Ogata Y et al. Prevention of delayed bleeding with vonoprazan in upper gastrointestinal endoscopic treatment. J. Gastroenterol. 2021; 56: 640-650.
Ishida T, Dohi O, Yamada S et al. Clinical outcomes of vonoprazan-treated patients after endoscopic submucosal dissection for gastric neoplasms: a prospective multicenter observation study. Digestion. 2021; 102: 386-396.

Auteurs

Yoshito Hayashi (Y)

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.

Waku Hatta (W)

Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Yosuke Tsuji (Y)

Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Toshiyuki Yoshio (T)

Division of Gastroenterology, Cancer Institute Hospital, Tokyo, Japan.

Yohei Yabuuchi (Y)

Division of Endoscopy, Shizuoka Cancer Center, Nagaizumi, Japan.

Shu Hoteya (S)

Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan.

Shigetsugu Tsuji (S)

Department of Gastroenterology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan.

Yasuaki Nagami (Y)

Department of Gastroenterology, Osaka City University Graduate School of Medicine, Osaka, Japan.

Takuto Hikichi (T)

Department of Endoscopy, Fukushima Medical University Hospital, Fukushima, Japan.

Masakuni Kobayashi (M)

Department of Endoscopy, The Jikei University School of Medicine, Tokyo, Japan.

Yoshinori Morita (Y)

Department of Gastroenterology, Kobe University International Clinical Cancer Research Center, Kobe, Japan.
Department of Gastroenterology, Kobe University Graduate School of Medicine, Kobe, Japan.

Tetsuya Sumiyoshi (T)

Department of Gastroenterology, Tonan Hospital, Sapporo, Japan.

Mikitaka Iguchi (M)

Second Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.

Hideomi Tomida (H)

Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Matsuyama, Japan.

Takuya Inoue (T)

Division of Gastroenterology and Hepatology, Osaka General Medical Center, Osaka, Japan.

Tatsuya Mikami (T)

Division of Endoscopy, Hirosaki University Hospital, Hirosaki, Japan.

Kenkei Hasatani (K)

Department of Gastroenterology, Fukui Prefectural Hospital, Fukui, Japan.

Jun Nishikawa (J)

Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.

Tomoaki Matsumura (T)

Department of Gastroenterology, Chiba University Graduate School of Medicine, Chiba, Japan.

Hiroko Nebiki (H)

Department of Gastroenterology, Osaka City General Hospital, Osaka, Japan.

Dai Nakamatsu (D)

Department of Gastroenterology, Toyonaka Municipal Hospital, Toyonaka, Japan.

Ken Ohnita (K)

Department of Gastroenterology and Hepatology, Nagasaki University Hospital, Nagasaki, Japan.

Haruhisa Suzuki (H)

Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan.

Hiroya Ueyama (H)

Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan.

Mitsushige Sugimoto (M)

Division of Digestive Endoscopy, Shiga University of Medical Science Hospital, Kusatsu, Japan.

Shinjiro Yamaguchi (S)

Division of Gastroenterology, Kansai Rosai Hospital, Amagasaki, Japan.

Tomoki Michida (T)

Department of Gastroenterology and Hepatology, Saitama Medical Center, Kawagoe, Japan.
Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.

Tomoyuki Yada (T)

Division of Gastroenterology and Hepatology, Kohnodai Hospital, National Center for Global Health and Medicine, Tokyo, Japan.

Yoshiro Asahina (Y)

Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan.

Toshiaki Narasaka (T)

Division of Endoscopic Center, University of Tsukuba Hospital, Tsukuba, Japan.

Shiko Kuribayashi (S)

Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi, Japan.

Shu Kiyotoki (S)

Department of Gastroenterology, Shuto General Hospital, Yanai, Japan.

Katsuhiro Mabe (K)

Department of Gastroenterology, National Hospital Organization Hakodate National Hospital, Hakodate, Japan.
Junpukai Health Maintenance Center Kurashiki, Okayama, Japan.

Akimitsu Miyake (A)

Department of Medical Innovation, Osaka University Hospital, Suita, Japan.

Mitsuhiro Fujishiro (M)

Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Atsushi Masamune (A)

Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Tetsuo Takehara (T)

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH